Carcinoid syndrome

European Journal of Surgical Oncology

Volumn 34, Issue 3, 2008, Pages 289-296

  Bendelow, J ^a   Apps, E ^a   Jones, L E ^a   Poston, G J ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Carcinoid syndrome

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLTYROSYL OCTREOTIDE; 1,4,8,11 TETRAAZACYCLOTETRADECANE N,N',N'',N''' TETRAACETIC ACID COPPER 64; ANGIOPEPTIN; BEVACIZUMAB; BORTEZOMIB; COPPER 64; CYCLAM; CYCLAM DERIVATIVE; DOPA; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GEFITINIB; IMATINIB; OCTREOTIDE; PENTETREOTIDE IN 111; STREPTOZOCIN; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANEMIA; CARCINOID; CARCINOID SYNDROME; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG EFFICACY; HEPATIC ARTERY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMAGE ANALYSIS; KIDNEY DYSFUNCTION; LYMPHOCYTOPENIA; METASTASIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCINTIGRAPHY; SYMPTOM; THROMBOCYTOPENIA; VOMITING;

EID: 39849090661     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.07.202     Document Type: Review

References (175)

1. M.H. Kulke R.J. Mayer Carcinoid tumors N Engl J Med 1999 858 867
2. I.M. Modlin A. Sandor An analysis of 8305 cases of carcinoid tumors Cancer 79 1997 813 829
3. E.D. Williams M. Sandler The classification of carcinoid tumours Lancet 1 1963 238 239
4. J.K. Ramage S.M. Catnach R. Williams Overview: the management of metastatic carcinoid tumors Liver Transpl Surg 1 1995 107 110
5. H.K. Bell G.J. Poston J. Vora N.J.E. Wilson Cutaneous manifestations of the malignant carcinoid syndrome Br J Dermatol 152 2005 71 75
6. I.M. Modlin M.D. Shapiro M. Kidd Carcinoid tumors and fibrosis: an association with no explanation Am J Gastroenterol 99 2004 2466 2478
7. L. Lundin I. Norheim J. Landelius Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound detectable cardiac abnormalities Circulation 77 1988 264 269
8. P.A. Robiolio V.H. Rigolin J.S. Wilson Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterisation and echocardiography Circulation 92 1995 790 795
9. P.A. Pellikka A.J. Tajik B.K. Khandheria Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients Circulation 87 1993 1188 1196
10. J.E. Moller P.A. Pellikka A.M. Bernheim Prognosis of carcinoid heart disease: analysis of 200 cases over two decades Circulation 112 2005 3320 3327
11. H.M. Connolly P.A. Pellikka Carcinoid heart disease Curr Cardiol Rep 8 2006 96 101
12. M.R. Thatipelli P.A. Uber M.R. Mehra Isolated tricuspid stenosis and heart failure: a focus on carcinoid heart disease Congest Heart Fail 9 2003 294 296
13. P.F. Quaedvlieg C.B. Lamers B.G. Taal Carcinoid heart disease: an update Scand J Gastroenterol Suppl 236 2002 66 71
14. W.C. Meijer D.J. van Veldhuisen I.P. Kema Cardiovascular abnormalities in patients with a carcinoid syndrome Neth J Med 60 2002 10 16
15. S. Di Luzio V.H. Rigolin Carcinoid heart disease Curr Treat Options Cardiovasc Med 2 2000 399 406
16. D.V. Simula W.D. Edwards H.D. Tazelaar Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years Mayo Clin Proc 77 2002 139 147
17. H.M. Connolly H.V. Schaff C.J. Mullany Surgical management of left-sided carcinoid heart disease Circulation 104 2001 136 140
18. H.M. Connolly H.V. Schaff C.J. Mullany Carcinoid heart disease: impact of pulmonary valve replacement in right ventricular function and remodelling Circulation 106 2002 151 156
19. P.A. Robiolio V.H. Rigolin J.K. Harrison Predictors of outcome of tricuspid valve replacement in carcinoid heart disease Am J Cardiol 75 1995 485 488
20. H.M. Connolly R.A. Nishimura H.C. Smith Outcomes of cardiac surgery for carcinoid disease J Am Coll Cardiol 25 1995 410 416
21. K. Kobayashi T. Katsumata S. Yoshizawa Indications for endoscopic polypectomy for rectal carcinoids and clinical usefulness of endoscopic ultrasonography Dis Colon Rectum 48 2005 285 291
22. M.A. Anderson S. Carpenter N.W. Thompson Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas Am J Gastroenterol 96 2000 2271 2277
23. G. Kaltsas A. Rockall D. Papdogias Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours Eur J Endocrinol 151 2004 15 27
24. J.F. Schaefer J. Vollmar F. Schick Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging – perfusion differences in malignant and benign lesions Radiology 232 2004 544 553
25. M.D. Seemann G. Meisatschlaeger J. Gaa E.J. Rummeny Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI Eur J Med Res 11 2006 58 65
26. S.W.J. Lamberts W.H. Bakker J.C. Reubi E.P. Krenning Somatostatin-receptor imaging in the localization of neuroendocrine tumors N Engl J Med 323 1990 1246 1249
27. E.P. Krenning D.J. Kwekkeboom H.Y. Oei Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors: an overview of European results Ann N Y Acad Sci 733 1994 416 424
28. 111In-DTPA- d -Phe1] octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment Eur J Endocrinol 131 1994 577 581
29. G. Savelli G. Lucignani E. Seregni Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours Nucl Med Commun 25 2004 445 449
30. T. Reisine G. Bell Molecular biology of somatostatin receptors Endocr Rev 16 1995 427 442
31. C. Bousquet J. Guillermet F. Vernejoul Somatostatin receptors and regulation of cell proliferation Dig Liver Dis 36 S1 2004 S2 S7
32. L.J. Hofland S.W. lamberts Somatostatin receptor subtype expression in human tumors Ann Oncol 12 S2 2001 S31 S36
33. H. Kulaksiz R. Eissele D. Rossler Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with specific antibodies Gut 50 2002 52 60
34. 111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours Br J Surg 90 2003 549 554
35. 111In-labelled octreotide derivatives Eur J Nucl Med 27 2000 1318 1325
36. M. Gabriel C. Decristoforo T. Maina 99mTc-N4-[Tyr3]octreotate versus 99mTc-EDDA/HYNIC-[Tyr3]octreotide: an interpatient comparison of two novel technetium-99m labelled tracers for somatostatin receptor scintigraphy Cancer Biother Radiopharm 19 2004 73 79
37. G.J. Forster M.J. Engelbach J.J. Brockmann Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide Eur J Nucl Med 28 2001 1743 1750
38. A. Otte J. Mueller-Brand S. Dellas Yttrium-90-labelled somatostatin analogue for cancer treatment Lancet 351 1998 417 418
39. C.A. Hoefnagel V.J. Lewington MIBG therapy I.P.C. Murray P.J. Ell Nuclear medicine vol. 2 1994 Churchill Livingstone Edinburgh 851 864
40. 131I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome Eur J Surg Oncol 27 2001 404 408
41. G. Kaltsas M. Korbonits E. Heintz Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors J Clin Endocrinol Metab 86 2001 895 902
42. B. Eriksson M. Bergstrom H. Orlefors Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies Q J Nucl Med 44 2000 68 76
43. A. Sundin B. Eriksson M. Bergstrom PET in the diagnosis of neuroendocrine tumors Ann N Y Acad Sci 1014 2004 246 257
44. B. Eriksson M. Bergstrom A. Sundin The role of PET in localization of neuroendocrine and adrenocortical tumors Ann N Y Acad Sci 970 2002 159 169
45. H. Orlefors A. Sundin U. Garske Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography J Clin Endocrinol Metab 90 2005 3392 3400
46. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors J Nucl Med 42 2001 213 221
47. 18F dopa PET for detection of gastrointestinal carcinoid tumors Radiology 220 2001 373 380
48. 18F-DOPA PET: a prospective, diagnostic accuracy study Lancet Oncol 7 2006 728 734
49. I. Virgolini P. Patri C. Novotny Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy Ann Oncol 12 2 2001 S41 S45
50. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors Mol Imaging Biol 5 2003 42 48
51. R.S. Chamberlain D. Canes K.T. Brown Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190 2000 432 445
52. R. Sutcliffe D. Maguire J. Ramage Management of neuroendocrine liver metastases Am J Surg 187 2004 39 46
53. J.M. Sarmiento F.G. Que Hepatic surgery for metastases from neuroendocrine tumors Surg Oncol Clin N Am 12 2003 321 342
54. M.A. Kinney M.E. Warner D.M. Nagorney Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours Br J Anaesth 87 2001 447 452
55. H. Nave E. Mossinger H. Feist Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years Surgery 129 2001 170 175
56. J.G. Touzios J.M. Kiely S.C. Pitt Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241 2005 776 783
57. J.A. Norton R.S. Warren M.G. Kelly Aggressive surgery for metastatic liver neuroendocrine tumors Surgery 134 2003 1057 1063
58. Z.S. el Rassi L. Ferdinand R.M. Mohsine Primary and secondary liver endocrine tumors: clinical presentation, surgical approach and outcome Hepatogastroenterology 49 2002 1340 1346
59. J.M. Sarmiento G. Heywood J. Rubin Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival J Am Coll Surg 197 2003 29 37
60. C.D. Knox I.D. Feurer P.E. Wise Survival and functional quality of life after resection for hepatic carcinoid metastases J Gastrointest Surg 8 2004 653 659
61. J.A. Soreide J.A. van Heerden G.B. Thompson Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients World J Surg 24 2000 1431 1436
62. K.A. Yao M.S. Talamonti A. Nemcek Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors Surgery 130 2001 677 682
63. G.P. McEntee D.M. Nagorney L.K. Kvols Cytoreductive hepatic surgery for neuroendocrine tumors Surgery 108 1990 1091 1096
64. M.H. Chung J. Pisegna M. Spirt Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver Surgery 130 2001 954 962
65. S.A. Gulec T.S. Mountcastle D. Frey Cytoreductive surgery in patients with advanced-stage carcinoid tumors Am Surg 68 2002 667 671
66. P.J. Cozzi R. Englund D.L. Morris Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors Cancer 76 1995 501 509
67. F.J. Wessels S.R. Schell Radiofrequency ablation treatment of refractory carcinoid hepatic metastases J Surg Res 95 2001 8 12
68. P. Hellmann S. Ladjevardis B. Skogseid Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors World J Surg 26 2002 1052 1056
69. E.A. Dick R. Joarder M. de Jode MR-guided laser thermal ablation of primary and secondary liver tumours Clin Radiol 58 2003 112 120
70. A.R. Henn E.A. Levine W. McNulty R.J. Zagoria Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine symptoms Am J Roentgenol 181 2003 1005 1010
71. D. O'Toole F. Maire P. Ruszniewski Ablative therapies for liver metastases of digestive endocrine tumours Endocr Relat Cancer 10 2003 463 468
72. A. Gillams A. Cassoni G. Conway W. Lees Radiofrequency ablation of neuroendocrine liver metastases – the Middlesex experience Abdom Imaging 30 2005 435 441
73. Navarra G, Ayav A, Weber JC, et al. Short- and long-term results of intraoperative radiofrequency ablation of liver metastases.
74. T.D. Atwell J.W. Charboneau F.G. Que Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques Cardiovasc Intervent Radiol 28 2005 409 421
75. E.H. Jensen L. Kvols J.M. McLaughlin Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors Ann Surg Oncol 14 2007 1416 1423
76. I. Hirai W. Kimura A. Fuse Surgical management for metastatic liver tumors Hepatogastroenterology 53 2006 757 763
77. S. Musunuru H. Chen S. Rajpal Metastatic neuroendocrine hepatic tumors: resection improves survival Arch Surg 141 2006 1000 1004
78. L.M. Veenendaal I.H. Rinkes C.J. Lips R. van Hillegersberg Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy World J Surg Oncol 4 2006 35
79. D.A. Osborne E.E. Zervos J. Strosberg Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors Ann Surg Oncol 13 2006 572 581
80. P. Hodul M. Malafa J. Choi L. Kvols The role of cytoreductive surgery as an adjunct to the management of metastatic neuroendocrine carcinomas Cancer Control 13 2006 61 71
81. B. Givi S.J. Pommier A.K. Thompson Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival Surgery 140 2006 891 898
82. D. Elias L. Sideris G. Liberale Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas Surgery 137 2005 411 416
83. W.O. Bechstein P. Neuhaus Liver transplantation for hepatic metastases of neuroendocrine tumors N Y Acad Sci 733 1994 507 514
84. H. Lang K.J. Oldhafer A. Weimann Liver transplantation for metastatic neuroendocrine tumors Ann Surg 225 1997 347 354
85. Y.P. Le Treut J.R. Delpero B. Dousset Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: a 31-case French multicentric report Ann Surg 225 1997 355 364
86. J.A. Fernandez R. Robles C. Marin Role of liver transplantation in the management of metastatic neuroendocrine tumors Transplant Proc 35 2003 1832 1833
87. H. Ahlman S. Friman C. Cahlin Liver transplantation for treatment of metastatic neuroendocrine tumors Ann N Y Acad Sci 1014 2004 265 269
88. S. Florman B. Toure L. Kim Liver transplantation for neuroendocrine tumors J Gastrointest Surg 8 2004 208 212
89. A. Frilling M. Malago F. Weber Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients Liver Transpl 12 2006 1089 1096
90. F.G. van Vilsteren E.S. Baskin-Bey D.M. Nagorney Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival Liver Transpl 12 2006 448 456
91. C.D. Knox C.D. Anderson L.W. Lamps Long-term survival after resection for primary hepatic carcinoid tumor Ann Surg Oncol 10 2003 1171 1175
92. S.W. Fenwick J.I. Wyatt G.J. Toogood J.P. Lodge Hepatic resection and transplantation for primary carcinoid tumors of the liver Ann Surg 239 2004 210 219
93. S.R. Schell E.R. Camp J.G. Caridi I.F. Hawkins Jr. Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors J Gastrointest Surg 6 2002 664 670
94. S. Gupta M.M. Johnson R. Murthy Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival Cancer 104 2005 1590 1602
95. V. Meij J.M. Zuetenhorst R. van Hillegersberg Local treatment in unresectable hepatic metastases of carcinoid tumors: experiences with hepatic artery embolization and radiofrequency ablation World J Surg Oncol 3 2005 75
96. J.R. Strosberg J. Choi A.B. Cantor L.K. Kvols Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors Cancer Control 13 2006 72 78
97. S. Dominguez A. Denys I. Madeira Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours Eur J Gastroenterol Hepatol 12 2000 151 157
98. A. Roche B.V. Girish T. de Baere Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors Eur Radiol 13 2003 136 140
99. O. Kress H.J. Wagner M. Wied Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors – a retrospective single-center analysis Digestion 68 2003 94 101
100. G. Fiorentini S. Rossi F. Bonechi Intra-arterial chemoembolization in liver metastases from neuroendocrine tumors: a phase II study J Chemother 16 2004 293 297
101. X.D. Dong X. Yin H.J. Zeh Long-term outcome in patients with liver metastases from neuroendocrine tumors treated with chemoembolization [abstract 4167] Proc Am Soc Clin Oncol Annu Meet 23 2005 349S
102. S. Gupta J.C. Yao K. Ahrar Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the MD Anderson experience Cancer J 9 2003 261 267
103. K. Oberg L. Kvols M. Caplin Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastrointestinal system Ann Oncol 15 2004 966 973
104. J. Rubin J. Ajani W. Schirmer Octreotide acetate long-acting formulation versus open-labelled subcutaneous octreotide acetate in malignant carcinoid syndrome J Clin Oncol 17 1999 600 606
105. P.L. Filosso E. Ruffini A. Oliaro Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide Eur J Cardiothorac Surg 21 2002 913 917
106. J. Garland J.R. Buscombe C. Bouvier Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience Aliment Pharmacol Ther 17 2003 437 444
107. S.V. Welin E.T. Janson A. Sundin High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours Eur J Endocrinol 151 2004 107 112
108. E. Woltering P.M. Mamikunian S. Zeitz Octreotide acetate (LAR) dose effect on plasma octreotide levels: impact on neuroendocrine tumor management Proc Am Soc Clin Oncol Annu Meet 23 2005 235S [abstract 3177]
109. V. Fykse A.K. Sandvik G. Qvigstad Treatment of ECL cell carcinoids with octreotide LAR Scand J Gastroenterol 39 2004 621 628
110. P. Tomassetti M. Migliori L. Gullo Slow-release lanreotide treatment in endocrine gastrointestinal tumors Am J Gastroenterol 93 1998 1468 1471
111. A.N.M. Wymenga B. Eriksson P.I. Salmela Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms J Clin Oncol 17 1999 1111 1117
112. S. Ricci A. Antonuzzo L. Galli Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide Ann Oncol 11 2000 1127 1130
113. M. Ducreux P. Ruszniewski J.A. Chayvialle The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors Am J Gastroenterol 95 2000 3276 3281
114. S. Ricci A. Antonuzzo L. Galli Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors Am J Clin Oncol 23 2000 412 415
115. D. O'Toole M. Ducreux G. Bommelaer Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance Cancer 88 2000 770 776
116. K.E. Imtiaz P. Monteith A. Khaleeli Complete histological regression of metastatic carcinoid tumour after treatment with octreotide Clin Endocrinol 53 2000 755 758
117. W.L. Leong J.L. Pasieka Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature J Surg Oncol 79 2002 180 187
118. M. Bondanelli M.R. Ambrosio M.C. Zatelli Regression of liver metastases of occult carcinoid tumour with slow release lanreotide therapy World J Gastroenterol 11 2005 2041 2044
119. D. Granberg B. Eriksson E. Wilander Experience in treatment of metastatic pulmonary carcinoid tumors Ann Oncol 12 2001 1383 1391
120. 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice Ann Oncol 11 2000 1437 1443
121. 131I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG Nucl Med Commun 21 2000 755 761
122. J.J. Mukherjee G.A. Kaltsas N. Islam Treatment of metastatic carcinoid tumours, phaeochromocytomas, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG] Clin Endocrinol 55 2001 47 60
123. L. Kolby P. Bernhardt A.M. Levin-Jakobsen Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters Br J Cancer 89 2003 1383 1388
124. 131I-meta-iodobenzylguanidine in the management of midgut carcinoid tumors World J Surg 28 2004 1157 1162
125. S.D. Safford R.E. Coleman J.P. Gockerman Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients Cancer 101 2004 1987 1993
126. C.H.J. van Eijck Treatment of advanced endocrine gastroenteropancreatic tumours using radiolabelled somatostatin analogues Br J Surg 92 2005 1333 1334
127. G.D. Slooter W.A. Breeman R.L. Marquet Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver Int J Cancer 81 1999 767 771
128. 111In-pentetreotide. State of the art perspectives Q J Nucl Med 44 2000 88 95
129. 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor South Med J 93 2000 809 811
130. 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors J Nucl Med 44 2003 1 6
131. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study Ann Oncol 12 2001 941 945
132. C. Waldherr M. Pless H.R. Maecke Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC J Nucl Med 43 2002 610 616
133. R. Valkema L.K. Kvols S. Pawels Peptide receptor radiotherapy (PRRT) with [Y-90-DOTA, Tyr3]octreotide: toxicity and efficacy of 4-cycle and single-cycle regimens [abstract 3046] Proc Am Soc Clin Oncol Annu Meet 23 2004 206
134. 177Lu-DOTA0, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors J Clin Oncol 23 2005 2754 2762
135. D.J. Kwekkeboom J. Mueller-Brand G. Paganelli Overview of results of peptide receptor radionuclide therapy with 3 radiolabelled somatostatin analogs J Nucl Med 46 2005 62S 66S
136. 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid) J Endocrinol Invest 29 2006 563 567
137. E. Bajetta E. Bichisao S. Artale New clinical trials for the treatment of neuroendocrine tumors Q J Nucl Med 44 2000 96 101
138. G.A. Kaltsas J.J. Mukherjee A. Isidori Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil Clin Endocrinol 57 2002 169 183
139. K. Oberg Chemotherapy and biotherapy in the treatment of neuroendocrine tumours Ann Oncol 12 S2 2001 S111 S114
140. P. Rougier E. Mitry Chemotherapy in the treatment of neuroendocrine malignant tumors Digestion 62 S1 2000 73 78
141. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment Anticancer Res 21 2001 4087 4090
142. L. Kolby G. Persson S. Franzen B. Ahren Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated carcinoid tumours Br J Surg 90 2003 687 693
143. M. Hopfner A.P. Sutter A. Huether A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine BMC Cancer 4 2004 23
144. J.M. Zuetenhorst R.A. Valdes Olmos M. Muller Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours Endocr Relat Cancer 11 2004 553 561
145. U.F. Pape B. Wiedenmann Adding interferon-alpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours Cancer Treat Rev 29 2003 565 569
146. K. Stuart D.E. Levy T. Anderson Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group Invest New Drugs 22 2004 75 81
147. L.J. Wirth M.R. Carter P.A. Janne B.E. Johnson Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy Lung Cancer 44 2004 213 220
148. W. Sun S. Lipsitz P. Catalano Phase II/III study of doxorubacin with fluorouracil compared with streptozotocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281 J Clin Oncol 23 2005 4897 4904
149. R.L. Fine D.R. Fogelman S.M. Schreibman Effective treatment of neuroendocrine tumors with temozolomide and capecitabine [abstract 4216] Proc Am Soc Clin Oncol Annu Meet 23 2005 361S
150. S.M. Ansell H.C. Pitot P.A. Burch A phase II study of high-dose paclitaxel with advanced neuroendocrine tumors Cancer 91 2001 1543 1548
151. M.H. Kulke H. Kim K. Stuart A phase II study of docetaxel in patients with metastatic carcinoid tumors Cancer Invest 22 2004 353 359
152. T. Kegel A. Grothe M. Jordan Paclitaxel, carboplatin and etoposid (TCE) in the treatment of advanced neuroendocrine tumours [abstract 4263] Proc Am Soc Clin Oncol Annu Meet 23 2005 373S
153. F.T. Miranda D.R. Spigel J.D. Hainsworth Paclitaxel/carboplatin/etoposide (PCE) therapy for advanced poorly differentiated neuroendocrine (PDNE) carcinoma: a Minnie Pearl Cancer Network phase II trial [abstract 4058] Proc Am Soc Clin Oncol Annu Meet 23 2005 322S
154. M. Hopfner A.P. Sutter B. Berst A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839) Br J Cancer 89 2003 1766 1775
155. M. Kulke H.J. Lenz N.J. Meropol A phase 2 study to evaluate the efficacy and safety of SU11248 in patients with unresectable neuroendocrine tumors [abstract 4008] Proc Am Soc Clin Oncol Annu Meet 23 2005 310S
156. T.J. Hobday M. Mahoney C. Erlichman Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): a phase II Consortium (P2C) study [abstract 4084] Proc Am Soc Clin Oncol Annu Meet 23 2005 328S
157. J.C. Yao S. Charnsangavej S.C. Faria Rapid decrease in blood flow, blood volume and vascular permeability in carcinoid patients treated with bezacizumab [abstract 3013] Proc Am Soc Clin Oncol Annu Meet 23 2004 198
158. J.C. Yao C. Ng P.M. Hoff Improved progression free survival, and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab [abstract 4007] Proc Am Soc Clin Oncol Annu Meet 23 2005 309S
159. J.E. Mares S. Worah S.V. Mathew Increased rate of hypertension among patients with advanced carcinoid treated with bevacizumab [abstract 4087] Proc Am Soc Clin Oncol Annu Meet 23 2005 329S
160. K. Carr J.C. Yao A. Rashid A phase II trial of imatinib in patients with advanced carcinoid tumor [abstract 4124] Proc Am Soc Clin Oncol Annu Meet 23 2005 343
161. M.H. Shah D. Young H.L. Kindler Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors Clin Cancer Res 10 2004 6111 6118
162. I. Duran L. Le D. Saltman A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas [abstract 3096] Proc Am Soc Clin Oncol Annu Meet 23 2005 215S
163. N.K. Aaronson A. Cull S. Kaasa M. Sprangers The EORTC modular approach to quality of life assessment in oncology Int J Ment Health 23 2 1994 75 96
164. S.A. Shumaker M.J. Naughton The international assessment of health-related quality of life: a theoretical perspective S.A. Schumaker R. Bernzon The international assessment of health-related quality of life: theory, translation, measurement and analysis 1995 Rapid Communications of Oxford Oxford 3 10
165. G. Larsson K. Haglund L. Von Essen Distress, quality of life and strategies to ‘keep a good mood’ in patients with carcinoid tumours: patient and staff perceptions Eur J Cancer Care (Engl) 12 2003 46 57
166. G. Larsson P.O. Sjoden K. Oberg B. Eriksson L. Von Essen Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours Acta Oncol 40 2001 825 831
167. G. Larsson P.O. Sjoden K. Oberg L. Von Essen Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours Ann Oncol 10 1999 1321 1327
168. G. Larsson L. Von Essen P.O. Sjoden Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract Acta Oncol 38 1999 481 490
169. M.B. Jacobsen L.E. Hanssen Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial J Intern Med 237 1995 269 275
170. Jones LE. Patient perceptions and experiences of fatigue with metastatic carcinoid disease. MSc thesis, University of Liverpool; 2005.
171. A.H.G. Davies L. Friend L. Jones Development of a disease-specific EORTC quality of life score questionnaire for patients with gastrointestinal tumours Gut 2005
172. D.F. Cella D.S. Tulsky G. Gray The functional assessment of cancer therapy scale: development and validation of the general measure J Clin Oncol 11 1993 570 579
173. N.K. Aaronson M. Bullinger S. Ahmedzai A modular approach to quality of life assessment in cancer clinical trials Recent Results Cancer Res 111 1998 231 249
174. M.A. Sprangers A. Cull K. Bjordal M. Groenvold N.K. Aaronson The European organisation for research and treatment of cancer approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on quality of life Qual Life Res 2 4 1993 287 295
175. M.A. Sprangers A. Cull M. Groenvold K. Bjordal J. Blazeby N.K. Aaronson The European organisation for research and treatment of cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group Qual Life Res 7 4 1998 291 300